November 16, 2006Patent: US2006257852This web page summarizes information in PubChem about patent US2006257852.An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.United States Patent Bickerton et al . ( 10 ) Patent No . : US 10 , 130 , 701 B2 ( 45 ) Date of Patent : Nov . 20 , 2018AbstractThe present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.DescriptionFIELD OF THE INVENTIONThe present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.https://patents.google.com/patent/US10130701B2/enhttps://patentimages.storage.googleapis.com/…/US1013070…https://www.uspto.gov/
